HomeTagsJohnson & Johnson

Tag: Johnson & Johnson

biotech

Johnson & Johnson prostate cancer drug receives CHMP positive opinion

Jim Cornall - February 5, 2026

biotech

First precision therapy prostate cancer drug approved

Jim Cornall - December 17, 2025

biotech

CRS programme to feature Poolbeg Pharma trial

Jim Cornall - December 11, 2025

biotech

“Turning point in how we treat EGFR-mutated lung cancer”

Jim Cornall - September 10, 2025

biotech

Johnson & Johnson aiming to revolutionise plaque psoriasis treatment

Jim Cornall - July 24, 2025

biotech

Johnson & Johnson receives Priority Review for high-risk non-muscle invasive bladder cancer treatment

Jim Cornall - July 22, 2025

- Advertisement -

spot_img

Latest Articles

biotech

Base to Base biotech podcast 81: Breakthrough in shrinking tumours and restoring mitochondrial metabolism to address obesity

biotech

New bacteria discovered in DNA samples from prostate cancer patients

biotech

Estuary Biotherapeutics launches with $103m to develop gene therapies for kidney disease

biotech

Data show reduction in skin epigenetic age and systemic inflammatory biomarkers

biotech

Blood proteins may offer clues to gut health in coeliac disease